tiopronin

Trade name: thiola

Small moleculeapprovedOrphan Drug FDA

Approved

Aug 11, 1988

Tiopronin is a prescription thiol drug used primarily in the treatment of severe homozygous cystinuria. Patients with cystinuria excrete high levels of cystine in their urine and are at risk for kidney stone formation. Tiopronin is used as a second-line therapy to control the rate of cystine precipitation and excretion, and prevent kidney stone formation. It is used after a failure of the non-pharmacological first line treatment consisting of increased fluid intake, restriction of sodium and protein, and urinary alkalinization. As cystinuria is a relatively rare disease, tiopronin is classified as an orphan drug and is not patented in the United States. It is similar to d-penicillamine in use and efficacy, but offers the advantage of far less adverse effects. Tiopronin is dosed on an individual basis using close monitoring of urinary cystine concentrations and urinary output. Tiopronin is a chelating agent. It works by removing extra cystine (the cause of kidney stones) from the urine, which keeps the kidney stones from forming. It works by reacting with urinary cysteine to form a more soluble, disulfide linked, tiopronin-cysteine complex. — NCATS

Clinical trial activity

5 trials · 12 clinical orgs · 9 marketing orgs

Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started Dec 1, 2007 (NCT02734966)

Timeline

1980s

  1. Jan 17, 1986

    Orphan Drug Designation

  2. Aug 11, 1988

    Mission Pharmacal — Earliest FDA Approval

  3. Aug 11, 1988

    Mission Pharmacal — NDA Organization

2000s

  1. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jun 28, 2019

    Mission Pharmacal — NDA Secondary Org

  2. Jun 28, 2019

    Mission Pharmacal — Marketing Organization

2020s

  1. Apr 26, 2021

    Teva — Marketing Organization

  2. Jun 2, 2022

    Par Pharmaceuticals — Marketing Organization

  3. Jun 2, 2022

    Endo Pharmaceuticals — Marketing Organization

  4. Jun 2, 2022

    Bristol-Myers Squibb — Marketing Organization

  5. Jun 2, 2022

    PH HEALTH — Marketing Organization

  6. Aug 15, 2023

    Amneal Pharmaceuticals — Marketing Organization

  7. Jan 30, 2024

    Torrent Pharmaceuticals Limited — Marketing Organization

  8. Jun 2, 2026

    Casper Pharma LLC — Marketing Organization

Indications

Mechanism of action

  • Unspecified targetOTHER

    Reducing agent

    Prevents cysteine excretion

Approval history

  • approvedPriority reviewAug 11, 1988

Chemistry & pharmacology

Loading structure…

SMILES

CC(S)C(=O)NCC(O)=O
Mol. weight
163.195 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • acadione
  • acadione
  • acadione
  • alpha-mercaptopropionylglycine
  • alpha-mercaptopropionylglycine
  • alpha-mercaptopropionylglycine
  • alpha-mpg
  • capen
  • captimer
  • captimer
  • captimer
  • hepadigest
  • mercaptopropionylglycine
  • thiola
  • thiola
  • thiola
  • thiolpropionamidoacetic acid
  • thiopronin
  • thiopronine
  • tiopronin
  • tiopronin
  • tiopronin
  • tiopronin
  • tiopronin
  • tiopronin
  • tiopronin
  • tiopronin
  • tiopronin
  • tiopronin
  • tiopronin
  • (+/-)-tiopronin
  • tiopronine
  • tiopronine
  • tiopronine
  • α-mpg

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03663855Phase 2Dec 31, 2018New York University
NCT03879759Phase 2Aug 22, 2018Macquarie University, National Health and Medical Research Council, Australia, South West Sydney Local Health District, Sydney Local Health District, University of Sydney
NCT02125721N/AJun 1, 2012National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), New York University
NCT01095731Phase 2Apr 1, 2010Columbia University, University of Florida, University of Washington
NCT02734966Phase 2Dec 1, 2007Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, Jiao Tong University
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (12)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
New York UniversityAcademic/Hospital2222012
Columbia UniversityAcademic/Hospital1112010
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,LtdFor profit1112007
Jiao Tong UniversityAcademic/Hospital1012007
Macquarie UniversityAcademic/Hospital1012018
National Health and Medical Research Council, AustraliaGovernment1012018
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Government1012012
South West Sydney Local Health DistrictAcademic/Hospital1112018
Sydney Local Health DistrictGovernment1012018
University of FloridaAcademic/Hospital1012010
University of SydneyAcademic/Hospital1012018
University of WashingtonAcademic/Hospital1012010
12 organizations
Page 1 / 1

Marketing (13)

OrganizationOrg typeRelationshipDate
Amneal PharmaceuticalsFor profitMKTGAug 15, 2023
Bristol-Myers SquibbFor profitMKTGJun 2, 2022
Casper Pharma LLCFor profitMKTGJun 2, 2026
Endo PharmaceuticalsFor profitMKTGJun 2, 2022
Mission PharmacalFor profitNDAAug 11, 1988
Mission PharmacalFor profitNDA2Jun 28, 2019
Mission PharmacalFor profitMKTGJun 28, 2019
PH HEALTHFor profitMKTGJun 2, 2022
Par PharmaceuticalsFor profitMKTGJun 2, 2022
Par PharmaceuticalsFor profitSYNFeb 24, 2023
TevaFor profitMKTGApr 26, 2021
TevaFor profitSYNJul 22, 2024
Torrent Pharmaceuticals LimitedFor profitMKTGJan 30, 2024